220100.KQ
FutureChem Co.,Ltd
KOE · Healthcare · Drug Manufacturers - Specialty & Generic · KR
KRW 7,860.00
−1.38%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 20.6B | 18.7B | 17.3B | 14.0B | 12.6B |
| Cost of Revenue | 15.4B | 15.3B | 14.3B | 13.2B | 11.7B |
| Gross Profit | 5.2B | 3.4B | 3.0B | 758.3M | 861.9M |
| Operating Expenses | |||||
| R&D Expense | 5.9B | 3.6B | 4.2B | 2.4B | 7.6B |
| SG&A Expense | 5.2B | 2.0B | 1.8B | 6.8B | 1.6B |
| General & Admin Expense | 2.1B | 828.5M | 729.7M | 851.0M | 848.3M |
| Selling & Marketing Expense | 1.7B | 1.1B | 1.0B | 993.3M | 765.0M |
| Other Expenses | 3.4B | 5.6B | 6.5B | 9.00 | 4.5B |
| Total Operating Expenses | 14.5B | 11.1B | 12.5B | 9.2B | 13.8B |
| Cost and Expenses | 30.0B | 26.4B | 26.8B | 22.4B | 25.5B |
| Operating Income (EBIT) | (9.4B) | (7.7B) | (9.5B) | (8.4B) | (12.9B) |
| Non-Operating | |||||
| Interest Income | 804.9M | 881.9M | 871.8M | 1.4B | 785.6M |
| Interest Expense | 1.0B | 1.0B | 649.7M | 478.1M | 1.4B |
| Net Interest Income | (237.0M) | (160.4M) | 222.0M | 945.4M | (571.3M) |
| Other Non-Op Income/Expense | (1.6B) | (3.3B) | 72.0M | 1.7B | (1.1B) |
| Non-Operating Income (excl Interest) | 6.3B | — | (721.7M) | (2.2B) | (281.5M) |
| EBT (Pre-Tax Income) | (11.0B) | (11.1B) | (9.4B) | (6.7B) | (14.0B) |
| Income Tax Expense | 121.1M | 121.1M | 29.8M | 11.3M | 3.9M |
| Bottom Line | |||||
| Net Income | (11.1B) | (11.3B) | (9.4B) | (6.7B) | (14.0B) |
| Earnings from Cont. Ops | (11.1B) | (11.2B) | (9.4B) | (6.7B) | (14.0B) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (11.1B) | (11.3B) | (9.4B) | (6.7B) | (14.0B) |
| Per Share | |||||
| Basic EPS | (₩508) | (₩508) | (₩426) | (₩304) | (₩732) |
| Diluted EPS | (₩508) | (₩508) | (₩426) | (₩304) | (₩732) |
| Revenue Per Share | ₩888 | ₩843 | ₩783 | ₩632 | ₩659 |
| Shares | |||||
| Basic Shares Outstanding | 23.2M | 22.1M | 22.1M | 22.1M | 19.1M |
| Diluted Shares Outstanding | 23.3M | 22.1M | 22.1M | 22.1M | 19.1M |
| Profitability Metrics | |||||
| EBITDA | (5.4B) | (2.6B) | (2.6B) | (566.3M) | (8.1B) |
| D&A | 4.6B | 5.2B | 6.1B | 5.7B | 4.6B |
| EBIT | (10.0B) | (7.7B) | (8.7B) | (6.2B) | (12.7B) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026